ROSEN, A LEADING NATIONAL FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The class action lawsuit targets individuals or entities that sold or held Cerevel stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - The lawsuit claims that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements regarding a secondary stock offering, which allowed Bain to acquire shares at a discounted price before AbbVie's acquisition announcement [5] - Following the secondary offering, AbbVie announced its acquisition of Cerevel for $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Next Steps for Investors - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [2] - Interested parties can visit the provided link or contact Rosen Law Firm for more information on participating in the class action [3][6] - A lead plaintiff must file a motion with the court by June 3, 2025, to represent other class members [1][3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4] - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]